share_log

Allarity Therapeutics | DEF 14A: Definitive information statements

Allarity Therapeutics | DEF 14A: Definitive information statements

Allarity Therapeutics | DEF 14A：股东委托书决议
美股SEC公告 ·  07/01 16:50
Moomoo AI 已提取核心信息
Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.
Allarity Therapeutics, Inc. has announced a series of corporate actions and updates, including amendments to its Certificate of Incorporation and Equity Incentive Plan, as well as executive officer changes. The company has proposed amendments to decrease authorized shares from 750,500,000 to 250,500,000 and to limit the liability of directors and officers. These amendments are subject to stockholder approval at the Annual Meeting scheduled for July 26, 2024. Additionally, Allarity has entered into agreements with 3i, LP, including a secured promissory note and a waiver agreement related to a public offering. The company has also reported the termination of Chief Medical Officer Marie Foegh and the appointment of Thomas H. Jensen as Chief Executive Officer. Furthermore, Allarity has adopted a compensation recovery policy subject to clawback or recoupment and has detailed its non-employee director compensation policy, which includes limits on the value of awards and cash compensation.
Allarity Therapeutics, Inc.宣布了一系列企业行动和更新，包括修改其公司章程和股权激励计划，以及管理人员变动。公司已提议减少授权股份从7.505亿股到2.505亿股，并限制董事和高管的责任。这些修正案将在2024年7月26日的年度股东大会上提交股东批准。此外，Allarity与3i, LP签订了协议，包括一份担保期票和有关公开发行的豁免协议。公司还报道了首席医疗官Marie Foegh的离职和任命Thomas H. Jensen为首席执行官。此外，Allarity实施了补偿回收政策，其中包括夺回或追索，并详细说明了其非员工董事薪酬政策，其中包括奖励价值和现金补偿的限制。
Allarity Therapeutics, Inc.宣布了一系列企业行动和更新，包括修改其公司章程和股权激励计划，以及管理人员变动。公司已提议减少授权股份从7.505亿股到2.505亿股，并限制董事和高管的责任。这些修正案将在2024年7月26日的年度股东大会上提交股东批准。此外，Allarity与3i, LP签订了协议，包括一份担保期票和有关公开发行的豁免协议。公司还报道了首席医疗官Marie Foegh的离职和任命Thomas H. Jensen为首席执行官。此外，Allarity实施了补偿回收政策，其中包括夺回或追索，并详细说明了其非员工董事薪酬政策，其中包括奖励价值和现金补偿的限制。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息